Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Zai Lab Limited

Market Cap 2.04B 35.38B 1.78B 1.65B 1.54B 2.89B 193B 2.91B 19.62B 7.63B 94.9B 7.67B 7.5B 330B P/E 2026 *
-8.21x
P/E 2027 * -9.75x
Enterprise Value 1.6B 27.71B 1.4B 1.29B 1.21B 2.27B 151B 2.28B 15.36B 5.98B 74.32B 6.01B 5.88B 258B EV / Sales 2026 *
3.56x
EV / Sales 2027 * 2.78x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
3 years 270.64
Extreme 270.64
810
5 years 270.64
Extreme 270.64
2,446.85
10 years 270.64
Extreme 270.64
3,693.35
Manager TitleAgeSince
Chief Executive Officer 60 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 60 01/04/2014
Director/Board Member 82 01/01/2017
Director/Board Member 74 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
+43.36%-.--% - - 2.04B
-0.05%-0.99%+18.95%-21.92% 62.05B
-0.84%-4.48%+50.61%+196.38% 54.52B
-5.75%+29.50%+29.50%+29.50% 41.55B
-2.96%+4.99%-53.01%-60.20% 39.06B
+1.03%-0.26%+58.80%-32.60% 29.02B
-5.69%+14.17%+131.85%-50.60% 25.38B
+4.17%+0.25%+52.01%+65.14% 19.62B
-1.05%-1.44%-3.02%+139.59% 16.89B
+1.04%+2.25%+60.69%+111.01% 15.89B
Average +3.33%+2.11%+38.49%+41.81% 33.78B
Weighted average by Cap. -1.14%+0.90%+33.15%+37.47%

Financials

2026 *2027 *
Net sales 449M 7.77B 392M 363M 338M 635M 42.4B 640M 4.31B 1.68B 20.85B 1.68B 1.65B 72.42B 596M 10.32B 520M 481M 449M 843M 56.28B 850M 5.72B 2.23B 27.67B 2.24B 2.19B 96.13B
Net income -241M -4.17B -210M -195M -182M -341M -22.77B -344M -2.31B -900M -11.19B -904M -885M -38.88B -156M -2.71B -137M -126M -118M -222M -14.79B -223M -1.5B -585M -7.27B -587M -575M -25.26B
Net Debt -443M -7.68B -387M -358M -334M -628M -41.88B -632M -4.26B -1.66B -20.59B -1.66B -1.63B -71.52B -387M -6.71B -338M -313M -292M -548M -36.59B -552M -3.72B -1.45B -17.99B -1.45B -1.42B -62.5B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
18.18USD
Average target price
33.30USD
Spread / Average Target
+83.19%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!